These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 17143251)

  • 1. c-Met inhibition.
    Salgia R
    Clin Adv Hematol Oncol; 2006 Nov; 4(11):823-4. PubMed ID: 17143251
    [No Abstract]   [Full Text] [Related]  

  • 2. Small molecule c-Met kinase inhibitors: a review of recent patents.
    Porter J
    Expert Opin Ther Pat; 2010 Feb; 20(2):159-77. PubMed ID: 20100000
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Novel therapeutic inhibitors of the c-Met signaling pathway in cancer.
    Eder JP; Vande Woude GF; Boerner SA; LoRusso PM
    Clin Cancer Res; 2009 Apr; 15(7):2207-14. PubMed ID: 19318488
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting the MET oncogene in cancer and metastases.
    Stella GM; Benvenuti S; Comoglio PM
    Expert Opin Investig Drugs; 2010 Nov; 19(11):1381-94. PubMed ID: 20868306
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Developing c-MET pathway inhibitors for cancer therapy: progress and challenges.
    Liu X; Newton RC; Scherle PA
    Trends Mol Med; 2010 Jan; 16(1):37-45. PubMed ID: 20031486
    [TBL] [Abstract][Full Text] [Related]  

  • 6. MET receptor tyrosine kinase.
    Faoro L; Cervantes GM; El-Hashani E; Salgia R
    J Thorac Oncol; 2009 Nov; 4(11 Suppl 3):S1064-5. PubMed ID: 19861919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.
    Zificsak CA; Theroff JP; Aimone LD; Albom MS; Angeles TS; Brown RA; Galinis D; Grobelny JV; Herbertz T; Husten J; Kocsis LS; LoSardo C; Miknyoczki SJ; Murthy S; Rolon-Steele D; Underiner TL; Wells-Knecht KJ; Worrell CS; Zeigler KS; Dorsey BD
    Bioorg Med Chem Lett; 2011 Jan; 21(2):660-3. PubMed ID: 21190849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor.
    Sadiq AA; Geynisman DM; Salgia R
    J Thorac Oncol; 2011 Nov; 6(11 Suppl 4):S1810-1. PubMed ID: 22005540
    [No Abstract]   [Full Text] [Related]  

  • 9. Have Clinical Trials Properly Assessed c-Met Inhibitors?
    Hughes VS; Siemann DW
    Trends Cancer; 2018 Feb; 4(2):94-97. PubMed ID: 29458966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Drug development of MET inhibitors: targeting oncogene addiction and expedience.
    Comoglio PM; Giordano S; Trusolino L
    Nat Rev Drug Discov; 2008 Jun; 7(6):504-16. PubMed ID: 18511928
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MET receptor juxtamembrane exon 14 alternative spliced variant: novel cancer genomic predictive biomarker.
    Ma PC
    Cancer Discov; 2015 Aug; 5(8):802-5. PubMed ID: 26243862
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MET inhibitors start on road to recovery.
    Garber K
    Nat Rev Drug Discov; 2014 Aug; 13(8):563-5. PubMed ID: 25082276
    [No Abstract]   [Full Text] [Related]  

  • 13. Enzastaurin, a protein kinase Cbeta- selective inhibitor, and its potential application as an anticancer agent in lung cancer.
    Herbst RS; Oh Y; Wagle A; Lahn M
    Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4641-6. PubMed ID: 17671157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
    Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
    Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Molecular cancer therapy: can our expectation be MET?
    Migliore C; Giordano S
    Eur J Cancer; 2008 Mar; 44(5):641-51. PubMed ID: 18295476
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 2021 World Conference on Lung Cancer.
    Landman A
    Lancet Oncol; 2021 Oct; 22(10):e429. PubMed ID: 34537087
    [No Abstract]   [Full Text] [Related]  

  • 17. A selective small molecule inhibitor of c-Met, PHA665752, inhibits tumorigenicity and angiogenesis in mouse lung cancer xenografts.
    Puri N; Khramtsov A; Ahmed S; Nallasura V; Hetzel JT; Jagadeeswaran R; Karczmar G; Salgia R
    Cancer Res; 2007 Apr; 67(8):3529-34. PubMed ID: 17440059
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Discovery of a novel and potent series of thieno[3,2-b]pyridine-based inhibitors of c-Met and VEGFR2 tyrosine kinases.
    Claridge S; Raeppel F; Granger MC; Bernstein N; Saavedra O; Zhan L; Llewellyn D; Wahhab A; Deziel R; Rahil J; Beaulieu N; Nguyen H; Dupont I; Barsalou A; Beaulieu C; Chute I; Gravel S; Robert MF; Lefebvre S; Dubay M; Pascal R; Gillespie J; Jin Z; Wang J; Besterman JM; MacLeod AR; Vaisburg A
    Bioorg Med Chem Lett; 2008 May; 18(9):2793-8. PubMed ID: 18434145
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Discovery of a novel mode of protein kinase inhibition characterized by the mechanism of inhibition of human mesenchymal-epithelial transition factor (c-Met) protein autophosphorylation by ARQ 197.
    Eathiraj S; Palma R; Volckova E; Hirschi M; France DS; Ashwell MA; Chan TC
    J Biol Chem; 2011 Jun; 286(23):20666-76. PubMed ID: 21454604
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Flavonoids as RTK inhibitors and potential anticancer agents.
    Teillet F; Boumendjel A; Boutonnat J; Ronot X
    Med Res Rev; 2008 Sep; 28(5):715-45. PubMed ID: 18080331
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.